I-5577 Imatinib, Free Base, >99%

Synonyms : [CGP-57148B] [STI-571]

Related Terms : [Glamox] [Gleevec] [Glivec] [Genfatinib]

  • Size
  • US $
  • £
  • ¥
  • 1 g
  • 48
  • 44
  • 37
  • 7,700
  • Add to Cart Qty:
  • In stock
  • 2 g
  • 86
  • 80
  • 67
  • 13,700
  • Add to Cart Qty:
  • In stock
  • 5 g
  • 155
  • 144
  • 122
  • 24,800
  • Add to Cart Qty:
  • In stock
  • 10 g
  • 190
  • 177
  • 150
  • 30,400
  • Add to Cart Qty:
  • In stock

Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.

To receive a Formal Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities Free Shipping and Handling to the U.S. and 32 Other Countries
  • M.W. 493.60
  • C29H31N7O
  • [152459-95-5]
  • M.I. 14: 4902

Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 25 mg/mL with slight warming; soluble in ethanol at 5 mg/mL with slight warming; very poorly soluble in water; maximum solubility in plain water is estimated to be about 5-20 µM; buffers, serum, or other additives may increase or decrea. Disposal: A.

Select Lot Number to view Certificate of Analysis

View the SDS for this product

  • This research compound is the free base form of imatinib.  We also offer the methanesulfonate salt form of imatinib:  Cat. No. I-5508, Imatinib, Methanesulfonate Salt.
  • This imatinib product is the free base, whose CAS number is given above. The CAS number of the methanesulfonate salt is 220127-57-1.
  • NOTE: the trade names listed above under "Related Terms" are for imatinib-containing drug products and may apply variously to formulations of one or another form of imatinib, such as the free base, mesylate salt, or other forms.
  • Imatinib (as the methanesulfonate salt) is the active ingredient in the drug products sold under numerous trade names listed near the top of this page as "Related Terms". This drug has been approved in at least one country for use in patients with gastrointestinal stromal tumors, chronic myelogenous leukemia and a number of other malignancies. NOTE: THE IMATINIB SOLD BY LC LABORATORIES FOR RESEARCH IS NOT ANY OF THE IMATINIB-CONAINING DRUG PRODUCTS SOLD UNDER VARIOUS TRADE NAMES, AND IS NOT FOR HUMAN USE.
  • Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.
  • This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
  • Not available in some countries; not available to some institutions; not available for some uses.